Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 14/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463294 | 0.89 | MAOA (0.60) | MAOACYP2E1 | |
| SCHEMBL463290 | 0.88 | MAOA (0.52) | MAOAF10CYP2E1 | |
| SCHEMBL463440 | 0.87 | MAOA (0.47) | MAOAF10CYP2E1 | |
| SCHEMBL463709 | 0.87 | MAOA (0.49) | MAOAF10CYP2E1ITGB3ITGA2B | |
| SCHEMBL463412 | 0.84 | CYP2E1 (0.51) | MAOAF10CYP2E1 | |
| SCHEMBL411075 | 0.83 | GRM2 (0.41) | F10 | |
| SCHEMBL463336 | 0.83 | CYP2E1 (0.57) | MAOAF10CYP2E1 | |
| SCHEMBL469773 | 0.82 | MAOA (0.53) | MAOACYP2E1 | |
| SCHEMBL411144 | 0.82 | F10 (0.48) | MAOAF10 | |
| SCHEMBL14447143 | 0.79 | MAOA (0.47) | MAOAF10CYP2E1ABCB11ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | MAOA 853/4885F10 3187/4885CYP2E1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.